The Sensex and Nifty are poised to open lower on Wednesday, in line with global equities amid concerns about aggressive interest rate hikes from the U.S. Federal Reserve.
CBI says the accused was trying to exert undue influence on officers of CDSCO to waive the Phase III trial of "Insulin Aspart Injection".
Resurgence of interest and new technologies bring a huge opportunity for the vaccine development field, says Biocon CMD Kiran Mazumdar-Shaw.
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
Semglee is the only interchangeable biosimilar to Lantus, used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes.
FSN E-Commerce breaks into top 100 mcap club with a valuation of $14 billion.
Biocon's executive chairperson Dr Kiran Mazumdar Shaw, calls for a PLI scheme specially focused on incentivising biopharma investment.
The executive chairperson of Biocon exhorts the government to revisit pharma price controls from a global perspective, in order to incentivise local manufacturing in the industry.
Kiran Mazumdar-Shaw, the Biocon chief, feels hospitalisation and not infection count matters in the fight against Coronavirus.
In an exclusive conversation with Fortune India, the executive chairperson of Biocon says India should immediately start mixing and matching existing vaccines to accelerate the vaccination drive.
